Pozen's PA8140/PA32540 receives a complete response letter from FDA citing issues at a facility of a third party supplier of an active Ingredient

28-04-2014 Business Wire HealthComments (0)


Pozen (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that their drug candidates PA8140/PA32540 (aspirin and omeprazole) delayed release tablets have received a complete response letter (CRL) from the US Food and Drug Administration (FDA). A CRL is issued by the FDA when the review of the file is completed and questions remain that preclude the approval of the new drug application (NDA)

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top